Egyptian Restaurant Serves Unconventional Sandwiches

Tourists are seen next to a meal made by Saqqara residents, who
sell food to improve their living conditions in thier village, in
Giza, Egypt, on April 27, 2021. REUTERS/Shokry Hussien
Tourists are seen next to a meal made by Saqqara residents, who sell food to improve their living conditions in thier village, in Giza, Egypt, on April 27, 2021. REUTERS/Shokry Hussien
TT

Egyptian Restaurant Serves Unconventional Sandwiches

Tourists are seen next to a meal made by Saqqara residents, who
sell food to improve their living conditions in thier village, in
Giza, Egypt, on April 27, 2021. REUTERS/Shokry Hussien
Tourists are seen next to a meal made by Saqqara residents, who sell food to improve their living conditions in thier village, in Giza, Egypt, on April 27, 2021. REUTERS/Shokry Hussien

In a step toward innovation and breaking the traditional, an Egyptian restaurant is serving unconventional “sandwiches”, offering its customers the chance to try diverse tastes including the meat of pigeons, ostriches, and ducks.

Located in the Nasr City, eastern Cairo, the Zouzou Restaurant, which is set to open a new branch in the October City, promotes its special sandwiches, their ingredients, and how they are prepared with videos on its official Facebook page.

The restaurant serves duck and turkey shawarma prepared in the same traditional way with onion, tomato, pepper, hot pepper, spices, and various sauces, but served in local bread. Shawarma choices are many and satisfy all tastes with new flavors, including pastrami, sausage, and traditional meat shawarma.

The “Hawawshi” sandwich are served with a twist as well; the best kind is “Hawawshi Zouzou”, a mix of spinach, mushroom, and smoked beef. There are also the pastrami hawawshi, hamburger, and local sausage. Turkey or liver hawawshi are also available in different sizes, including the ‘mini’ hawawshi of pastrami, liver, or sausage stuffing accompanied with different kinds of cheese such as mozzarella.

The idea of the restaurant consists of serving unfamiliar sandwiches made of meats that customers are used to eat in different ways.

“The restaurant is trying to change the old typical view of protein consumption by serving it in the form of “sandwich”. Eating pigeons or ducks doesn’t require a table and many utensils anymore. Now, you can eat it in a new, easy way,” Amro al-Soubki, manager of the Zouzou restaurant, told Asharq Al-Awsat.

For more innovation, the restaurant has reintroduced some of its most popular dishes with different “stuffing” choices, like the turkey shawarma sandwich seasoned with coriander and pineapple sauce; or the duck shawarma soaked in sweet orange juice, dill, honey mustard sauce, and tahini.

Alongside the non-traditional sandwiches, the Zouzou restaurant is experimenting with Tajines. It serves ostriches tajin, which according to the chef, “helps reduce blood cholesterol, and address many digestif problems.” “Ostrich meat is highly demanded because they are cooked fresh, right after the slaughter,” he added.

Tawouk has a share of innovation too. At the Zouzou restaurant, Tawouk is made of duck, or turkey soaked in yogurt, herbs, and spices. Among the other unfamiliar plates served at Zouzou are the ostrich steak and “mumbar” bites (mumbar are ‘animal intestines’ cleaned and stuffed with rice, spices, and tomato juice, then cut and fried).

“Serving protein in a sandwich has opened the door for more innovations that we will launch soon, including the ‘veal akawi’. Although ostrich meat is expensive and not so popular in Egypt, it’s among the most demanded plates, alongside hawawshi and shawarma,” said Soubki.

In addition to the popular, traditional shawarma, the restaurant also serves the pastrami shawarma with sliced olive and cheese mix, as well as shawarma of sausage, smoked beef, or mushroom and other types of vegetables like spinach.

Egyptian are used to pigeons stuffed with rice or grits, but at Zouzou, it’s served as “Kofta”, made of boneless pigeon meat mixed with onions and spices, and served as small rings, or with rice.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”